CJC-1295 vs Sermorelin
Both are GHRH analogs acting on the same receptor. The real difference is regulatory: sermorelin has a pediatric clinical record and a compounding route; CJC-1295 is research-only.
Short answer
Both have human clinical data behind them, which makes the goal the real difference between CJC-1295 and sermorelin. For a reader focused on muscle and recovery, CJC-1295 is the relevant choice; sermorelin is marketed for GH deficiency. For CJC-1295, single injections raised GH 2- to 10-fold for six days or more in healthy adults (2006); no outcome trials.
CJC-1295
Sustained GH/IGF-1 rise shown in humans — a surrogate marker, not the body-composition outcome it is sold for.
Full CJC-1295 evidence reviewSermorelin
Geref
A former FDA-approved GHRH analog (now compounded); real GH-axis data, no anti-aging outcome evidence.
Full Sermorelin evidence reviewCJC-1295 vs Sermorelin: head to head
- FDA status / approved use
CJC-1295
Not approved for any marketed use; sold as a research-use-only productSermorelin
Used for diagnosing and treating childhood GH deficiency; branded US injectable discontinued for commercial reasons- Marketed for
CJC-1295
Muscle, recovery, 'anti-aging'Sermorelin
GH deficiency, 'anti-aging'- Outcome areas
CJC-1295
Muscle / strength / lean mass; Injury recovery / tissue repair; Longevity / lifespanSermorelin
Longevity / lifespan- Evidence grade
CJC-1295
Clinical dataSermorelin
Clinical data- How it works
CJC-1295
Long-acting GHRH analog that stimulates growth hormone releaseSermorelin
GHRH analog that prompts the pituitary to release the body's own growth hormone- Route and dosing
CJC-1295
InjectionSermorelin
Injection- Headline human result
CJC-1295
Single injections raised GH 2- to 10-fold for six days or more in healthy adults (2006); no outcome trialsSermorelin
IGF-1 rose from 159.5 to 239.0 ng/mL in 14 hypogonadal men on a GHRP/sermorelin combination (2017); no outcome trials- Strongest evidence
CJC-1295
Teichman, JCEM 2006CJC-1295 evidence reviewPubMed 16352683Sermorelin
BioDrugs review, 1999Sermorelin evidence reviewPubMed 18031173- Key safety signal
CJC-1295
No long-term human safety data; chronic GH/IGF-1 stimulation raises concernsSermorelin
GH-axis effects on glucose handling, fluid retention and joints; theoretical IGF-1 proliferative concerns- How it is obtained
CJC-1295
Sold gray-market as a research chemical; no approved or legitimately compounded human productSermorelin
Prescribed and dispensed by compounding pharmacies; legality varies by compound
| CJC-1295 | Sermorelin | |
|---|---|---|
| FDA status / approved use | Not approved for any marketed use; sold as a research-use-only product | Used for diagnosing and treating childhood GH deficiency; branded US injectable discontinued for commercial reasons |
| Marketed for | Muscle, recovery, 'anti-aging' | GH deficiency, 'anti-aging' |
| Outcome areas | Muscle / strength / lean mass; Injury recovery / tissue repair; Longevity / lifespan | Longevity / lifespan |
| Evidence grade | Clinical data | Clinical data |
| How it works | Long-acting GHRH analog that stimulates growth hormone release | GHRH analog that prompts the pituitary to release the body's own growth hormone |
| Route and dosing | Injection | Injection |
| Headline human result | Single injections raised GH 2- to 10-fold for six days or more in healthy adults (2006); no outcome trials | IGF-1 rose from 159.5 to 239.0 ng/mL in 14 hypogonadal men on a GHRP/sermorelin combination (2017); no outcome trials |
| Strongest evidence | Teichman, JCEM 2006CJC-1295 evidence reviewPubMed 16352683 | BioDrugs review, 1999Sermorelin evidence reviewPubMed 18031173 |
| Key safety signal | No long-term human safety data; chronic GH/IGF-1 stimulation raises concerns | GH-axis effects on glucose handling, fluid retention and joints; theoretical IGF-1 proliferative concerns |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Prescribed and dispensed by compounding pharmacies; legality varies by compound |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
Sermorelin is the better documented of the two, though its evidence-backed role is narrow: the diagnosis and treatment of idiopathic growth-hormone deficiency in children. Its anti-aging use rests on biomarker effects rather than healthspan outcomes. CJC-1295 has one strong human pharmacology result, sustained multi-day elevations in GH and IGF-1 after single injections, but that is a surrogate marker, and CJC-1295 is not approved for anything; it is sold research-only, with unverified dose and purity. The two have not been compared directly, and neither has human body-composition outcome data.
CJC-1295 fits if
CJC-1295 is the molecule to read about if your question is how long a GHRH signal can be stretched pharmacologically; it is not a prescribable product.
Sermorelin fits if
Sermorelin is the more relevant one for a reader working with a clinician, since it has a genuine clinical history and is still supplied through compounding pharmacies.
CJC-1295 vs Sermorelin: common questions
- Is either CJC-1295 or sermorelin FDA-approved?
- No. CJC-1295 is not approved for any marketed use; sold as a research-use-only product. Sermorelin is used for diagnosing and treating childhood GH deficiency; branded US injectable discontinued for commercial reasons.
- Which has stronger human evidence, CJC-1295 or sermorelin?
- Neither clearly. Both have human clinical data. The key source for CJC-1295 is Teichman, JCEM 2006; for sermorelin, it is BioDrugs review, 1999.
- What are the main safety concerns with CJC-1295 and sermorelin?
- CJC-1295 has no long-term human safety data; chronic GH/IGF-1 stimulation raises concerns. For sermorelin, watch for GH-axis effects on glucose handling, fluid retention and joints; theoretical IGF-1 proliferative concerns.
Key studies behind each
CJC-1295
- Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. PubMed 9849822
- Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. PubMed 16352683
- Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. (2009). Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. PubMed 19289567
- Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. PubMed 25331030
Sermorelin
- Prakash A, Goa KL. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. PubMed 18031173
- Sigalos JT, Pastuszak AW, Allison A, et al. (2017). Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health. PubMed 28830317
- Sinha DK, Balasubramanian A, Tatem AJ, et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. PubMed 32257855
- Baker LD, Barsness SM, Borson S, et al. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. PubMed 22869065
The full evidence reviews
- Ipamorelin & CJC-1295: the honest evidence on GH secretagogue peptides
They reliably raise growth hormone, and that part is real. The muscle, fat-loss and anti-aging claims are not supported by human outcome data. A straight read.
Updated October 2026
- Sermorelin benefits: does it work? What the trials show
A real GHRH drug, read against the anti-aging pitch: an approved growth-hormone-releasing analog with a pediatric track record, and a longevity case built more on biomarkers than outcomes.
Updated October 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm CJC-1295 & Ipamorelin availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: California Trim ClinicDr. Gillis' Wellness CenterElitePhysiqMDEmbraceRXIron Med RXJune Health